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A single broadly reactive standard ELISA is commonly applied to control small 24 
ruminant lentivirus (SRLV) spread, but type specific ELISA strategies are gaining interest 25 
in areas with highly prevalent and heterogeneous SRLV infections. Short (15-residue) 26 
synthetic peptides (n = 60) were designed in this study using deduced amino acid sequence 27 
profiles of SRLV circulating in sheep from North Central Spain and SRLV described 28 
previously. The corresponding ELISAs and two standard ELISAs were employed to 29 
analyse sera from sheep flocks either controlled or infected with different SRLV 30 
genotypes. Two outbreaks, showing SRLV-induced arthritis (genotype B2) and 31 
encephalitis (genotype A), were represented among the infected flocks. The ELISA results 32 
revealed that none of the assays detected all the infected animals in the global population 33 
analyzed, the assay performance varying according to the genetic type of the strain 34 
circulating in the area and the test antigen.  35 
Five of the six highly reactive (57-62%) single peptide ELISAs were further 36 
assessed, revealing that the ELISA based on peptide 98M (type A ENV-SU5, consensus 37 
from the neurological outbreak) detected positives in the majority of the type-A specific 38 
sera tested (Se: 86%; Sp: 98%) and not in the arthritic type B outbreak. ENV-TM ELISAs 39 
based on peptides 126M1 (Se: 82%; Sp: 95%) and 126M2 0,65 0.77  (Se: 68%; Sp: 88%)  40 
detected preferentially caprine arthritis encephalitis (CAEV, type B) and Visna/Maedi 41 
(VMV, type A) virus infections respectively, which may help to perform a preliminary 42 
CAEV vs. VMV-like typing of the flock. The use of particular peptide ELISAs and 43 
standard tests individually or combined may be useful in the different areas under study, to 44 
determine disease progression, diagnose/type infection and prevent its spread. 45 
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1. Introduction 48 
The control of small ruminant lentiviruses (SRLV), which include the Visna/Maedi 49 
virus (VMV) and the caprine arthritis encephalitis virus (CAEV), largely depends on early 50 
detection and elimination of infected animals from the flock (Patel et al., 2012). Therefore, 51 
the use of the relevant assay and its updating becomes essential (Lacerenza et al., 2006; 52 
Reina, 2009 #360). Main antibody detection methods include agar gel immunodiffusion 53 
(AGID), linked immunosorbent assay (ELISA), and the confirmatory techniques 54 
radioimmunoprecipitation (RIPA) and Western blot (WB) (de Andres et al., 2005; Reina et 55 
al., 2009b). AGID has been progressively substituted by ELISAs (Peterhans et al., 2004) 56 
with improved sensitivity and automation to detect serum, milk and semen antibodies (de 57 
Andres et al., 2005; Peterhans et al., 2004; Ramirez et al., 2009; Reina et al., 2009a). 58 
Although competitive ELISA methods based on monoclonal antibodies to viral envelope 59 
protein (ENV-SU, gp135) epitopes have been developed (Herrmann-Hoesing et al., 2010), 60 
indirect ELISAs have been the most frequently applied in Europe (Carrozza et al., 2009; 61 
Reina et al., 2009a). However, few of these have been compared internationally (Brinkhof 62 
and van Maanen, 2007; Ramirez et al., 2009; Toft et al., 2007).  63 
Difficulties in ELISA antigen design strive mainly in the high antigenic and genetic 64 
variability of SRLV, being these viruses classified into genotype A which involves 65 
classical VMV-like viruses, genotype B assigned to CAEV-like viruses (Shah et al., 2004), 66 
genotype C found in goats and sheep from Norway (Gjerset et al., 2009), genotype D 67 
observed in ruminants from Switzerland and Spain (Reina et al., 2006; Shah et al., 2004) 68 
and genotype E detected in Italian goats (Grego et al., 2007; Reina et al., 2009b). 69 
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Interestingly, genotype A derived antigens seem more suitable than genotype B antigens to 70 
detect heterologous infection (Lacerenza et al., 2006). On the other hand, seroprevalence 71 
against genotype E may be underestimated using commercially available ELISAs 72 
(“standard” ELISAs henceforth) (Reina et al., 2009b).  73 
Control programs of Central and Southern Europe have employed indirect ELISAs 74 
based on whole virus or viral recombinant proteins (Reina et al., 2009a; Saman et al., 75 
1999; Zanoni et al., 1994), differing in performance according to the range of antigenic 76 
specificities or the antibody concentration required (Ramirez et al., 2009). Antibody titer 77 
may vary along the animal’s life (Varea et al., 2001), which may lead to misdiagnosis by 78 
ELISA. These findings, together with the high genetic/antigenic variability inherent to 79 
these viruses makes no single technique or test sufficient for use as "gold standard" to 80 
determine the infection status of the animal (Reina et al., 2009a). In the absence of this 81 
standard, the positivity to at least two diagnostic techniques, based on either antibody or 82 
virus-related detection, has been used in some studies as criterion for the presence of 83 
infection (Saman et al., 1999; Varea et al., 2001). 84 
In Spain, a country with over 30 million of small ruminants (about four times sheep 85 
compared to goats), SRLV infection affects from 10% to 90% of animals depending on the 86 
geographic area, and outbreaks with neurological (Glaria et al., 2012) and arthritic forms of 87 
the disease (Glaria et al., 2009) have been described in the North-Central area (Castilla-88 
León and Aragón, respectively). Together with the limited implementation of control 89 
programs, this has led to significant production and animal welfare losses. Like in other 90 
European countries, AGID has been replaced by indirect ELISAs (de Andres et al., 2005) 91 
in Spain. Comparison studies on different standard ELISAs have been initiated in Spanish 92 
goats (Contreras et al., 1998; Sanchez et al., 2001) and sheep (Ramírez et al., 2009). Elitest 93 
(Elitest-MVV Hyphen-Biomed, France) (Saman et al., 1999) has been successfully applied 94 
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alone and in combination with PCR, allowing an efficient detection of SRLV infection 95 
(Alvarez et al., 2006; Barquero et al., 2011; Leginagoikoa et al., 2006; Leginagoikoa et al., 96 
2010; Reina et al., 2006) and being implemented at present in areas of North-Central Spain 97 
(Leginagoikoa et al., 2010; Perez et al., 2010). As a result, some flocks have reached a 98 
seronegative status (Perez et al., 2010). However, like in other areas, seroconversion may 99 
reappear sporadically, decreasing the flock value (Brulisauer et al., 2005).  100 
This study, involving known and newly designed ELISA assays, aims to explore 101 
the possibilities of a fine tuning of ELISA testing in different areas infected with different 102 
SRLV, and proposes diagnostic strategies to prevent viral spread in these areas through 103 
flock typing and to detect infection in animals seronegative to standard assays.  104 
 105 
2. Materials and methods 106 
2.1. Animals and samples 107 
Two panels of sheep sera from North-Central Spain were used. In a preliminary 108 
study, aiming to determine the degree of reactivity of 60 peptides in an ELISA format, the 109 
panel of sera employed (n = 128) was obtained from different flocks widely distributed in 110 
this area, known to have type A (Glaria et al., 2012) and type B (Glaria et al., 2009) 111 
infections (Table 1). Most of these sera, 112 (87.5%) were known positives in one or both 112 
standard ELISAs, specifically 85 (66.4%) in Elitest, 108 (84.3%) in Chekit and 81 (63.2%) 113 
in both standard tests. At a second stage, a serum panel of increased size (involving 496 114 
additional animals) was used for a detailed study on reactivity patterns and specificities. 115 
Accordingly, animal Groups 1 to 6 were established from different flocks, with the 116 
following characteristics (Table 2 shows further details on groups’ description). Group 1 117 
was negative to VMV infection according to standard tests, without having been submitted 118 
to any control measure. Groups 2 and 6, both seronegative to Elitest, were from flocks 119 
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originally infected with SRLV but had been included in the last decade in an eradication 120 
program using Elitest until becoming seronegative to this test; Group 3 animals were from 121 
a flock infected with different SRLV types but free of diseased animals; and Groups 4 and 122 
5 were from SRLV infected flocks belonging to a neurological and an arthritic outbreak, 123 
respectively. Animals of the infected groups were further divided into positive (P) and 124 
negative (N) to Elitest in order to further analyze peptide ELISA reactivities compared to 125 
standard tests (Table 3). Also, for the study on disease status, sera from the arthritic and the 126 
neurological outbreaks were distributed into the clinically-affected and asymptomatic 127 
categories (Table 4). 128 
In addition, sera from 130 sheep and goats from UK, Italy and Iceland, belonging to 129 
flocks consistently SRLV-seronegative upon retesting, were used as negative controls to 130 
determine peptide ELISA cut-off values.  131 
The study on peptide ELISA strain specificity was done with sera from 71 animals 132 
infected with a known SRLV genotype (Figs. 1 and 2): 37 sheep from North-Central Spain 133 
naturally infected with genotypes A (n=28) and B (n=9), 10 sheep from the United 134 
Kingdom experimentally infected with strain Ev1 of genotype A  (Niesalla et al., 2009); 1 135 
sheep experimentally infected with the Icelandic clone Kv1772 from genotype A, kindly 136 
provided by Dr. V. Andrésdóttir; 15 Mexican goats naturally infected with genotype B1 137 
(Ramirez et al., 2011); and 8 Italian goats experimentally infected with genotype E 138 
Roccaverano strain (Reina et al., 2011). 139 
2.2. Peptide design 140 
 Peptides were designed on the basis of newly described sequences from two 141 
outbreaks of arthritis and neurological disease from Spain as well as sequences available 142 
from databases. The gag and env nucleotide sequences of SRLV present in Spanish 143 
animals were obtained using primers (Fig 1S, Annex I in Supplementary material) and the 144 
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PCR procedures described below. Deduced amino acid sequences were aligned with those 145 
available from GenBank database and analyzed 146 
(http://tools.immuneepitope.org/tools/bcell/iedb_input) regarding hydrophobicity, 147 
flexibility, accessibility, turns, exposed surface, polarity and antigenic propensity of 148 
polypeptide chains that have been correlated with the location of antibody epitopes 149 
(Kolaskar and Tongaonkar, 1990). After discarding non-antigenic regions, 60 peptides of 150 
15 amino acids each were designed (Fig 1S, Annex II in Supplementary material), 151 
corresponding to the viral nucleocapsid GAG p14 NC (n = 7), GAG p17 matrix MA (n = 152 
11), capsid GAG p25 CA (n = 13), surface envelope ENV gp135 SU (n = 8) and 153 
transmembrane ENV gp46 TM (n = 21) viral proteins.  154 
Peptides were chemically synthesized (Thermo scientific) and diluted upon arrival in 155 
carbonate buffer (pH 9.6) at 1 mg/ml and stored at -20ºC until tested in the corresponding 156 
screening ELISA.  157 
2.3. Peptide ELISA procedure 158 
Each peptide ELISA was carried out as previously described (Reina et al., 2009b), 159 
with slight modifications. Briefly, 96-well microplates (Maxisorp NuncTM) were coated 160 
with 300 ng of the selected peptide in carbonate buffer (pH 9.6) or carbonate buffer alone 161 
as negative control. Plates were allowed to dry overnight at 37ºC and then blocked with 162 
2.5% bovine casein for 1 h at 37ºC. After washing in PBS with 0.1% Tween 20, serum 163 
samples diluted 1/20 in PBS containing 1.25% bovine casein were added and plates 164 
incubated for 1 h at 37ºC. Subsequently, protein G (0.2 µg/ml, Pierce) diluted in the same 165 
buffer was added and plates were incubated for 1 h at 37ºC. After a final washing step, the 166 
reaction was developed with ABTS (Millipore) and absorbance read at 405 nm. Net 167 
absorbance was obtained by subtracting the absorbance in the well without antigen from 168 
the absorbance of the well with antigen.  169 
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2.5. Polymerase chain reaction (PCR) and sequencing  170 
PCR was used to determine the nucleotide sequences for peptide design and, when 171 
needed, to confirm the infection status. Briefly, genomic DNA was extracted from 172 
peripheral blood mononuclear cells (PBMC) or tissue samples (central nervous system or 173 
carpal joint from clinically affected animals of the neurological and the arthritic outbreak, 174 
respectively) using QIAamp® DNA Blood Mini Kit (Qiagen) as described elsewhere 175 
(Crespo et al 2012). Tissue samples were previously lysed (1 h at 56ºC) in buffer (100 mM 176 
Tris-HCl pH 8.5; 5 mM EDTA; 400 mM NaCl; 0.2% SDS) with Proteinase K (50 µg per 177 
107 cells; Sigma).  178 
Gag and env regions were amplified with previously described primers (Glaria et 179 
al., 2009) or those designed in this work (Supplementary material). The reaction mix of the 180 
PCRs consisted of: 1× Reaction Buffer (Biotools), 2 mM MgCl2 (Biotools), 225 µM of 181 
each dNTP (Biotools), 600 nM of each primer, 0.04 U/µl of Pfu DNA polymerase 182 
(Biotools) and  0.5 to 1 µg of sample DNA to a final volume of 30 µl. PCR conditions 183 
were: initial denaturation step for 5 min at 94ºC followed by 45 cycles of 94ºC for 40 s, 184 
annealing at 50 to 58 ºC (depending on the primers used) for 50 s and extension at 72ºC for 185 
a variable period (depending on the size of the amplicon); and a final extension step (10 186 
min at 72ºC). Amplicons were cloned into pGEMT-easy® vector (Promega) following the 187 
manufacturer’s instructions and then sequenced using BigDye® Terminator v3.1 chemistry 188 
on a 3730 DNA Analyzer (Applied-Biosystems).  189 
2.5. Standard ELISAs 190 
Two standard ELISAs were used following the corresponding manufacturer’s 191 
instructions: Elitest  based on a GAG p25 recombinant protein and a TM synthetic peptide 192 
as antigens derived from genotype A (Saman et al., 1999); and Chekit (AG-CHEKIT 193 
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CAEV / MVV kit, IDEXX Switzerland) based on whole virus antigen (Zanoni et al., 194 
1994).  195 
2.6. Data analysis  196 
In the screening study of the 60 peptide ELISAs (first stage), the cut-off value was 197 
fixed to 0.35 according to reactivity of negative sera (mean value plus three times standard 198 
deviation), a value close to 0.3 applied previously in similar studies (Mordasini et al., 199 
2006). At a second stage, when 5 of these ELISAs were further investigated, the cut-off 200 
value was calculated individually for each peptide ELISA, using ROC curve analysis. 201 
Sensitivity and specificity of each ELISA test were determined using 2 by 2 contingency 202 
tables. The associated 95% confidence intervals (CI) were estimated using Exact Binomial 203 
test (RCoreTeam, 2012). 204 
Fisher’s exact test was used for comparisons of frequencies of binomial data 205 
(positive/negative). Between-group differences of absorbance and index means were 206 
submitted to analysis of variance and means comparison using the PROC GLM of the SAS 207 
statistical package (SAS institute, Cary, NC. USA), with the Tukey-Kramer adjustment for 208 
multiple comparisons in the LSMEANS statement. Differences were considered 209 
statistically significant if p <0.05. Estimates of agreement between tests using kappa and 210 
confidence intervals (CI 95 %) were obtained as described previously (Landis and Koch, 211 
1977). Analysis of correlation was applied to assess the relationships between the different 212 
tests using the CORR procedure of the SAS statistical package.  213 
 214 
3. Results 215 
3.1. Preliminary peptide screening  216 
The 60 synthesized peptides were used individually as coating antigens in ELISA 217 
assays. For a preliminary peptide screening using field samples, the panel of 128 sera (112 218 
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positive to Elitest and/or Chekit) from sheep of North Central Spain was tested in the 219 
peptide ELISAs. The results obtained on the degree of reactivity presented by each of the 220 
60 peptide ELISAs (Table 1) indicate that few of the peptide ELISAs (10%) were highly 221 
reactive, with positive results at a frequency close to that observed of positive reactions to 222 
two commercial tests, Elitest and Chekit (around 60%). This preliminary screening 223 
allowed us to select for further studies five of these peptides [91 and 98M (envelope 224 
surface, SU region), 126M1, 126M2 and 139 (envelope transmembrane, TM region)]. 225 
Peptide 91 ELISA, was used as a low-reactivity ELISA control assay and the other four 226 
ELISAs were highly reactive (Table 1).   227 
 228 
3.2. Reactivity of sera in the ELISAs according to the genotype of the infecting virus  229 
In order to determine the type of antibody specificity detected by the five selected 230 
peptide ELISAs and to assess the sensitivity and specificity of these ELISAs, a group of 231 
infected animals (n = 71) was used to obtain PCR and sequencing data so that the virus 232 
was genotyped in each of these animals. Also, a cut-off value was established in each of 233 
the five ELISAs, using for this the negative control serum panel (n = 130). None of the 234 
sera of this control panel reacted beyond the positivity threshold value in the peptide 235 
ELISAs. To assess the antibody specificity detected by each of the peptide ELISAs (91, 236 
98M, 126M1, 126M2 and 139), the provirus from 71 animals from different sources (as 237 
specified in the Material and Methods section) was genotyped by gag PCR-sequencing, 238 
alignment and phylogenetic analysis (Fig 1). 239 
Sera from these animals were distributed into three groups according to the genotypes (A, 240 
B and E) of the SRLV infecting the animals, and then tested in the peptide ELISAs (Fig. 241 
2). The results indicated that genotype E was very poorly detected by these peptides. 242 
Peptide 98M (consensus sequence from the neurological outbreak; Fig. 2S of the 243 
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Supplementary material) detected almost exclusively genotype A infections (including 244 
those by Spanish 697, Icelandic Kv1772 and Scottish Ev1 strains), distinguishing it from 245 
infections with other genotypes (p <0.0001 for ELISA mean absorbance comparisons on 246 
genotype A vs. genotypes B or E). This is in line with a previous study in which this 247 
peptide was able to discriminate between animals affected with neurological vs. arthritic 248 
disease (Glaria et al., 2011). In contrast with 98M, peptide 126M1 reacted especially with 249 
genotype B infected sera (p < 0.001) from Spanish (B2) and Mexican (B1) origins, as 250 
observed in mean comparisons vs. genotype A or genotype B vs. E (p < 0.005). Similarly, 251 
mean comparisons of peptide 126M2 ELISA results allowed the distinction between A and 252 
B infections although cross-reacting antibodies were detected at a higher proportion 253 
compared to 126M1 ELISA. Finally, peptide 139 detected low percentages of infected 254 
animals either with genotype A or B. A detail on the sensitivity and specificity values of 255 
each peptide ELISA is provided in Table 5 and the corresponding ROC curves in Fig. 3. 256 
The group of negative sera obtained from the different European countries, were not 257 
reactive in the peptide ELISAs, confirming the very low proportion of false positive 258 
reactions in these assays. Overall, these results reveal the utility of peptide ELISAs to 259 
detect and distinguish in a group of animals, genotype A vs. B infections and the existence 260 
of an association between the antibody specificity detected by peptide ELISAs and the 261 
type-specific antigen design.  262 
 263 
 3.3. Detection of clinical vs. asymptomatic infections by peptide ELISAs  264 
Knowing that TM peptides may detect preferentially clinical SRLV infections 265 
(Bertoni et al., 1994), we determined if any of the four ENV highly reactive peptides 266 
(98M, 126M1, 126M2 or 139) reacted preferentially with SRLV affected animals from the 267 
arthritic or neurological outbreaks. SRLV-infected animals analyzed in each outbreak were 268 
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distributed into diseased vs. asymptomatic categories and the results obtained with the 269 
peptide ELISAs compared (Table 4). Statistical differences between reaction frequencies 270 
showed that clinical stages were detected preferentially with peptide 139 ELISA in both 271 
outbreaks. Furthermore, when considering jointly both outbreaks, clinical stages were 272 
preferentially detected with the peptide 139 ELISA and tended to be preferentially detected 273 
with peptide 126M1 also from the TM region. Independently of the clinical vs. 274 
asymptomatic status, sera reacted more frequently in the 98M (genotype A) and 126M1 275 
(genotype B) ELISAs when they were obtained from the neurological and the arthritic 276 
outbreaks, respectively, in agreement with the genotype-related results shown in Fig. 1. 277 
None of the standard tests yielded significant differences in any of the comparisons of this 278 
table.  279 
 280 
3.4. Serological studies in animal groups of North Central Spain  281 
Five of the eight most reactive peptides ELISAs were selected for further studies, 282 
and these as well as both standard tests (Elitest and Chekit) were tested against a large 283 
panel of sera (n = 496) collected in North Central Spain. In the three groups infected 284 
according to standard tests (3, 4 and 5; Table 2), the main genetic types of circulating 285 
SRLVs were firstly established by PCR-sequencing of a representative sample of animals 286 
within each group. Accordingly, these were of types A (Group 4); B (Group 5); and either 287 
A or B (Group 3).  288 
Overall (global population, Table 2), sera showed an intermediate degree of 289 
reactivity (frequency of positive reactions close to 50%) in both standard tests and in the 290 
joint result of the five peptide ELISAs (not shown), but the reactivity decreased to 26-291 
34.7% when the four most reactive peptide ELISAs were individually considered and 292 
down to 6.6% in the case of peptide 91 ELISA. This is in line with the results obtained 293 
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with the reduced serum panel (n = 128; Table 1), with the lack of reaction observed with 294 
the uninfected control sera under study (n = 130), and with the correspondence existing 295 
between the antigen type of both the circulating strain and the ELISA peptide. 296 
Analysis of results per group revealed that Groups 1 and 2, both negative to Elitest, 297 
showed limited positive results to Chekit and most of the peptides, but in Group 1 a 298 
substantial proportion (40%) of the animals were seropositive to 98M ELISA. Among the 299 
infected Groups (3, 4 and 5), Group 3 with mixed (types A and B) SRLV infections, 300 
presented a higher reactivity in Chekit compared to Elitest and 126M2 was the most 301 
reactive peptide (Table 2). In Group 4 (neurological outbreak, type A) both standard tests 302 
performed similarly, but with a slightly decreased frequency compared to 98M ELISA. In 303 
Group 5 (arthritic outbreak, type B), Chekit detected more positives than Elitest and 304 
126M1 was the most sensitive ELISA. Finally, Group 6 positives were only detected by 305 
peptide ELISAs, 126M1 and 126M2 being the most reactive. 306 
The proportion of discordant reactions between both standard tests varied between 307 
animal groups and the proportion of the animals negative to one or both standard tests but 308 
positive to a peptide ELISA varied between animal groups and between peptide ELISAs.  309 
The four most reactive peptide ELISAs differed from each other in reactivity 310 
patterns, according to the main circulating SRLV type of the animal group. In all the cases, 311 
peptides detected infections according to their antigenic design, thus genotype A infections 312 
were better detected with peptide 98M (Group 4) and genotype B infections were detected 313 
mainly with 126M1 (Group 5).  314 
 Among the animals from groups 3, 4 and 5 positive to Elitest (Table 3), the highest 315 
proportion of positives to peptide ELISAs was found in Group 4P with type A infections 316 
(91.6% in 98M ELISA), followed by Group 5 with type B infections (72.5% in 126M1 317 
ELISA) and Group 3 with mixed (A and B) infections (50% in 126M1 ELISA).  318 
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Analysis of sera from the Elitest negative groups, revealed that Groups 2 and 6 319 
(both certified by Elitest) did not reach 30 percent reactivity in any of the peptide ELISAs 320 
and did not react in Chekit. However, sera from Group 1 (naturally negative to Elitest) had 321 
a reactivity similar to that found in group 4N (Table 3) from A-infected flocks, reaching 322 
reactivity levels well above 30 percent in peptide 98M ELISA and of 14-23 percent in 323 
Chekit.  324 
To further assess if Elitest-negative animals with a substantial reactivity to 98M 325 
ELISA were truly infected, a follow up study was done one year later on Group 4-Elitest-326 
N, involving 48 animals which were analyzed by PCR, standard tests and peptide ELISAs. 327 
The results corroborated that the group was infected, since 6 of the animals became Elitest 328 
positive and 20 of the animals were found infected according to PCR. PCR analysis 329 
revealed that most of these animals were infected (16 of the amplicons were sequenced) by 330 
genotype A and of these, the majority (75%) were seropositive in peptide 98M ELISA 331 
(genotype A antigen) and in the Chekit assay.  332 
Taken together, these results indicate that the peptide ELISAs enable general and 333 
especially type specific serotyping of infected animal groups according to the reactivity 334 
pattern differences between them.  335 
 336 
4. Discussion 337 
A single diagnostic assay is commonly applied to detect SRLV infections in each 338 
particular area under study. However, SRLV are heterogeneous, the strains circulating in 339 
different areas may differ from each other and thus the performance of diagnostic tests in 340 
these areas might vary accordingly. In this work, we explored comparatively different 341 
ELISA-based strategies in animals infected with different genotypes of SRLV in areas of 342 
North-Central Spain. The assays involved in the work were two standard tests, Elitest and 343 
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Chekit, and ELISAs based on different synthetic peptides derived from SRLV proteins of 344 
genotypes A and B.   345 
The tendency towards an increased ability of type-A strain antigens to detect cross-346 
reacting antibodies in type B infections has been recognized previously (Lacerenza et al., 347 
2006). Consequently, type A derived antigens become less discriminatory at the time of 348 
distinguishing infections of the types A and B. This occurred here when comparing the 349 
ELISAs of peptide 126M2 (type A-derived) vs. 126 M1 (type B-derived) or Elitest 350 
(derived from type A strain) vs. Chekit, whose reactivity appeared to be directed mainly 351 
towards genotype B infection even though this assay involves the MVV OLV whole virus 352 
antigen (Zanoni et al 2004). On the other hand, the Chekit assay, based on whole virus 353 
protein, may have covered a broader antigen spectrum compared to Elitest, which is based 354 
on a two component monostrain design (TM synthetic peptide and p25 recombinant 355 
protein). This may partially explain the Elitest-negative Chekit-positive results obtained 356 
(54 of the 496 sera; 10.88%). In the area of study vaccination against BTV serotypes 1 and 357 
8 had been performed since 2008 (Sánchez Matamoros et al., 2009). Whether the Chekit 358 
assay detected also antibodies BTV-related but unrelated to SRLV (Valas et al., 2011) is 359 
unknown, since paired serial samples were unavailable. In agreement with previous reports 360 
(Reina et al., 2010), both assays, Elitest and Chekit, may have underestimated genotype E 361 
seroprevalence as they were not fully detecting animals experimentally infected with a 362 
strain of this genotype. Comparatively in the global population, each of the standard tests 363 
detected infection more efficiently than single peptide ELISAs (with exceptions like 98M 364 
ELISA in the Castilla-León region), likely because both standard tests displayed at least 365 
two viral proteins as coating antigens. Thus, peptide combinations may be required to 366 
increase the antigenic spectrum. However, standard ELISAs failed to detect a proportion of 367 
animals seropositive to peptide ELISAs and were less informative than peptide ELISAs 368 
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regarding the genotyping of the infection present in a particular area, so relevant in 369 
epidemiological studies, control of virus spread and animal exchange programs.   370 
Only eight of the 60 peptides screened were highly reactive, suggesting that these 371 
eight peptides corresponded to well conserved antigenic regions along the viral genome. 372 
Peptide 77 (77/GAG p14; Table 2) ELISA had apparently a high reactivity but positivity 373 
could not be confirmed in a high proportion of animals by PCR or standard ELISAs (or 374 
peptide ELISAs presented here). Therefore, many positive reactions against peptide 77 375 
may have been non-specific. Lack of reactivity to the remaining peptides tested was 376 
unexpected, although the probability of any epitope prediction algorithm to identify a real 377 
epitope is usually less than 60%. Several reports using WB based on both matrix and 378 
capsid proteins have shown that these proteins are highly reactive with sera from naturally 379 
and experimentally infected animals, suggesting that linear epitopes are located in these 380 
antigenic regions (Houwers and Nauta, 1989; Rosati et al., 1994; Zanoni et al., 1989). This 381 
could be due to the algorithm chosen for epitope prediction, length of the selected region 382 
and efficiency of passive immobilization on solid phase which is strictly sequence 383 
dependent. In line with this, the highest performance among the four highly reactive 384 
peptide ELISAs studied in depth corresponded to the peptide ELISA 98M, but only when 385 
applied to detect type-A specific antibodies (as expected since 98M was in a type-specific 386 
amino acid region), elicited in experimental infections with Ev1 strain (Reina et al., 2008), 387 
the Kv1772 clone (Andresson et al., 1993) or natural infections such as those of the 388 
Castilla-León region (Group 4). This peptide corresponds to an immunodominant epitope 389 
of a variable region (Fig 2S of Supplementary material) homologous to that of the SU5 390 
peptide 1163 detecting antibodies with high avidity (Mordasini et al., 2006). In contrast, 391 
peptide 91 ELISA had by far the lowest performance in the screening study (n = 128), as 392 
well as in the second-phase study (n = 496). Likely, the immunodominance of this epitope 393 
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was hindered, since its sequence included a conserved cysteine among the available SRLV 394 
sequences downstream a potential N-linked glycosylation site (Valas et al., 2000), but 395 
lacked a precedent glycosylation site.  In line with previous findings (Glaria et al., 2009), a 396 
single inversion within the amino acid sequence (HQ in 126M1 and QH in 126M2; Table 397 
1) biased the peptide reactivity towards a CAEV-like (B-type) and a VMV-like (A-type) 398 
profile, respectively. Type-specific reactivity of the three ENV-TM peptides was less 399 
marked than that of the ENV-SU 98M peptide corresponding to the hypervariable domain 400 
SU5, in agreement with previous studies (Mordasini et al., 2006). Compared to the Elitest 401 
ENV-TM peptide (Saman et al., 1999), 126M1 and 126M2 were shorter, lacking residues 402 
GGQ at the amino-terminal and KS at the carboxy-terminal, which may affect the antigen 403 
coating. 404 
Amongst the three animal groups (1, 2 and 6) apparently uninfected (Elitest-405 
negative), Group 1 was found positive mainly according to peptide 98M ELISA, strongly  406 
suggesting genotype A infections may trigger anti-ENV-SU (98M) antibodies undetectable 407 
by the p25 or the ENV-TM peptide used in Elitest. In addition, Groups 2 and 6 were 408 
similarly reactive in peptide 126M1 and 126M2 ELISAs, suggesting the presence of two 409 
circulating genotypes (A and B) in these flocks. Thus, the selection of peptides for 410 
complementary tools may differ between areas in this scenario of known virus genotype. 411 
Particularly in Elitest-negative animals, genotype A infections may be detected by 98M 412 
and 126M2 ELISAs (in Groups 3 and 4), whereas genotype B infections may be detected 413 
by 126M1 ELISA (in Group 5). Therefore, peptide testing of animals assumed to be free of 414 
infection may help to detect and classify the infection avoiding its persistence.  415 
Sera from clinically affected animals tended to be more reactive with the peptide 416 
139 ELISA, which appeared to detect high affinity antibodies produced along with viral 417 
replication burst, disease onset and pathogenesis. CAEV-like TM peptides such as TM3, 418 
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analogous to 126M1, also detected preferentially clinical (type B) infections (Bertoni et al., 419 
1994). Thus, the frequency of non clinical infections as detected by ELISAs based on 420 
peptides 139 and 126M1 may be underestimated. TM3, 126M1 and 126M2 peptides have 421 
two cystein residues that may trigger the production of enhancing antibodies to favor viral 422 
entry, as it occurs in HIV infections (Robinson et al., 1991), undermining the role of early 423 
cellular responses (de Andres et al., 2009; Juganaru et al., 2011). However detection of 424 
these antibodies is less informative from the point of view of early diagnosis. 425 
Often the information on genetic types of circulating strains is not available and a 426 
unique serological diagnostic technique is applied blindly. In this scenario of unknown 427 
virus genotype, PCR-based techniques (Barquero et al., 2011; Brinkhof et al., 2010), WB 428 
(Ramirez et al., 2009) or the heteroduplex mobility assay may be helpful for initial 429 
classification of SRLV circulating genotypes (Germain et al., 2008; Germain and Valas, 430 
2006) enabling proper antigen design for new type specific ELISA. These ELISAs may be 431 
useful to diagnose infection in populations of limited size, animals of high value apparently 432 
seronegative or flocks close to an eradication stage and to trace back infections of 433 
epidemiological interest. The appearance of mixed infections, new variants by mutation, 434 
recombination or introduction of new viral types into flocks and herds, point out the need 435 
of constant surveillance on the technique implemented in order to improve diagnosis and 436 
control the virus spread.  437 
 438 
5. Conclusion 439 
This study, showing the results obtained with different diagnostic strategies in 440 
particular geographic areas involving heterogeneous SRLV infections, outlines the interest 441 
of peptide assays to type the infections and control viral spread and encourages the 442 
development of highly sensitive ELISA tests involving multiple strain designs. 443 
19 
 
Conflict of interest statement 444 
None of the authors has personal or financial relationship with people or 445 
organization that could influence or bias the results presented in this paper. Experimental 446 
results and test designs and procedures produced in this paper, including ELISAs and 447 
newly characterized sequences are patent pending.  448 
Acknowledgements 449 
Funded by CICYT (AGL2010-22341-C04-01) and Government of Navarra 450 
IIQ010449.RI1 and IIQ14064.RI1. H. Ramírez was supported by PASPA program, 451 
UNAM and Public University of Navarra. R. Reina was supported by CSIC JAE-Doc 452 
contract. We sincerely acknowledge Valgerdur Andrésdóttir (University of Reykjavik) and 453 
Gordon D. Harkiss (University of Edinburgh), for kindly supplying sera from certified 454 






Andresson,  O.S.,  Elser,  J.E.,  Tobin,  G.J.,  Greenwood,  J.D.,  Gonda,  M.A.,  Georgsson,  G., 461 
Andresdottir,  V.,  Benediktsdottir,  E.,  Carlsdottir, H.M., Mantyla,  E.O.,  1993, Nucleotide 462 




on  blood  and  milk  samples  and  serological  survey  for  small  ruminant  lentiviruses  in 467 
central Spain. Vet Rec 168, 20. 468 
Bertoni, G., Zahno, M.L., Zanoni, R., Vogt, H.R., Peterhans, E., Ruff, G., Cheevers, W.P., Sonigo, P., 469 
Pancino, G., 1994, Antibody  reactivity  to  the  immunodominant epitopes of  the  caprine 470 
arthritis‐encephalitis virus gp38 transmembrane protein associates with the development 471 
of arthritis. J Virol 68, 7139‐7147. 472 
Brinkhof,  J., van Maanen, C., 2007, Evaluation of  five enzyme‐linked  immunosorbent assays and 473 
an  agar  gel  immunodiffusion  test  for  detection  of  antibodies  to  small  ruminant 474 
lentiviruses. Clin Vaccine Immunol 14, 1210‐1214. 475 




























an  arthritic  sheep  outbreak  demonstrates  the  introduction  of  CAEV‐like  viruses  among 502 
Spanish sheep. Vet Microbiol 138, 156‐162. 503 
Glaria, I., Reina, R., Ramirez, H., de Andres, X., Crespo, H., Jauregui, P., Salazar, E., Lujan, L., Perez, 504 
M.M.,  Benavides,  J.,  Perez,  V.,  Polledo,  L.,  Garcia‐Marin,  J.F.,  Riezu,  J.I.,  Borras,  F., 505 
Amorena,  B.,  de  Andres,  D.,  2012,  Visna/Maedi  virus  genetic  characterization  and 506 
serological diagnosis of  infection  in  sheep  from  a  neurological  outbreak. Vet Microbiol 507 
155, 137‐146. 508 
Grego, E., Bertolotti, L., Quasso, A., Profiti, M., Lacerenza, D., Muz, D., Rosati, S., 2007, Genetic 509 
characterization of small ruminant  lentivirus  in  Italian mixed flocks: evidence for a novel 510 
genotype circulating in a local goat population. J Gen Virol 88, 3423‐3427. 511 
Herrmann‐Hoesing,  L.M.,  Broughton‐Neiswanger,  L.E., Gouine,  K.C., White,  S.N., Mousel, M.R., 512 
Lewis,  G.S.,  Marshall,  K.L.,  Knowles,  D.P.,  2010,  Evaluation  of  a  caprine  arthritis‐513 
encephalitis virus/maedi‐visna virus  indirect enzyme‐linked  immunosorbent assay  in  the 514 





B., Rosati, S., 2011,  In vitro properties of small  ruminant  lentivirus genotype E. Virology 520 
410, 88‐95. 521 
Kolaskar,  A.S.,  Tongaonkar,  P.C.,  1990,  A  semi‐empirical  method  for  prediction  of  antigenic 522 
determinants on protein antigens. FEBS Lett 276, 172‐174. 523 
Lacerenza,  D.,  Giammarioli,  M.,  Grego,  E.,  Marini,  C.,  Profiti,  M.,  Rutili,  D.,  Rosati,  S.,  2006, 524 









Lujan,  L.,  Berriatua,  E.,  2010,  Effects  of  housing  on  the  incidence  of  visna/maedi  virus 532 
infection in sheep flocks. Res Vet Sci 88, 415‐421. 533 
Mordasini, F., Vogt, H.R., Zahno, M.L., Maeschli, A., Nenci, C., Zanoni, R., Peterhans, E., Bertoni, 534 
G.,  2006,  Analysis  of  the  antibody  response  to  an  immunodominant  epitope  of  the 535 
envelope glycoprotein of a lentivirus and its diagnostic potential. J Clin Microbiol 44, 981‐536 
991. 537 




Visna/maedi  virus  serology  in  sheep:  survey,  risk  factors  and  implementation  of  a 542 
successful control programme in Aragon (Spain). Vet J 186, 221‐225. 543 




Ramirez,  H.,  Glaria,  I.,  de  Andres,  X.,  Martinez,  H.A.,  Hernandez,  M.M.,  Reina,  R.,  Iraizoz,  E., 548 
Crespo,  H.,  Berriatua,  E.,  Vazquez,  J.,  Amorena,  B.,  de  Andres,  D.,  2011,  Recombinant 549 












Blacklaws,  B., Harkiss, G.D.,  2008, Mucosal  immunization  against  ovine  lentivirus  using 562 
PEI‐DNA  complexes  and modified  vaccinia Ankara  encoding  the  gag  and/or  env  genes. 563 
Vaccine 26, 4494‐4505. 564 






Development  of  specific  diagnostic  test  for  small  ruminant  lentivirus  genotype  E.  Vet 571 
Microbiol 138, 251‐257. 572 






E.,  Juste,  R., Mamoun,  R.Z.,  Rolland, M.,  Amorena,  B.,  de  Andres, D.,  2006, Molecular 577 
characterization and phylogenetic study of Maedi Visna and Caprine Arthritis Encephalitis 578 
viral sequences in sheep and goats from Spain. Virus Res 121, 189‐198. 579 
Robinson,  W.E.,  Jr.,  Gorny,  M.K.,  Xu,  J.Y.,  Mitchell,  W.M.,  Zolla‐Pazner,  S.,  1991,  Two 580 
immunodominant  domains  of  gp41  bind  antibodies  which  enhance  human 581 
immunodeficiency virus type 1 infection in vitro. J Virol 65, 4169‐4176. 582 













on  104  new  isolates:  evidence  for  regular  sheep‐to‐goat  transmission  and  worldwide 596 
propagation through livestock trade. Virology 319, 12‐26. 597 










(ovine progressive pneumonia) virus  seroconversion  in  field  sheep  samples.  J Vet Diagn 608 
Invest 13, 301‐307. 609 
Zanoni, R., Krieg, A., Peterhans, E., 1989, Detection of antibodies to caprine arthritis‐encephalitis 610 








Percentage of sera reactive to the 60 synthetic single peptidea ELISAs (1 type of peptide /ELISA) analyzed in this study using a panel of 
128 sera from sheep flocks of North Central Spain.  
No. of ELISAs  Reactivity (%)  Peptide name/viral protein-peptide amino acid sequence used in this study 
           33   Very low    (<9%) 
 
 
           15   Low    (9-20%) 
 
 





             2   High           (46-47%)  48/GAGp25-KLNEEAERWVRQNPP 
81/GAGp14-GNNRRGPRVVPSAPP 














Percentage of sera reactive in different areas of North Central Spain using five synthetic single peptide ELISAs (peptides 91, 98M, 




SRLV type a  
     Province   
     (region) 
             Breed/ outbreak Standard ELISA  Peptide ELISA 
    Elitest Chekit         91  98M  126M1   126M2    139  
 
 






















    2  (50) Vizcaya (País 
Vasco) 
Latxa 0 0  10 12 20 22 0  
    3  (62): A,B Navarra 
(Navarra) 
Mixed 45.2 71  16.1 22.5 32.2 29 8  
    4  (157): A León, Zamora 
(Castilla-León) 
Assaf/ neurologic  61.1 60.5  9 69.4 17.8 38.2 45.2  




87.2 100  5.1 6.8 66.6 41.8 41.8  
    6  (60) 
 
Global population 
tested (496): A, B 
Teruel (Aragón) 
 
All the tested 
provinces  






















            






Percentage of sera reactive in each of the five synthetic peptide ELISAs (91, 98M, 126M1, 126M2 and 139) and in the standard ELISA Chekit 
using infected groups (3, 4 and 5) and the global population tested, each distributed into positive (P) and negative (N) categories according to the 
standard Elitest results. 
Animal group, 
Elitest reaction  
        Peptide ELISA 
(No. of sera): SRLV type    Chekit         91  98M  126M1   126M2    139  
 
            
    3    Elitest P   (28): A,B    93  25 39.3 50 39.3 17.9  
          Elitest N  (34)    53  8.8 8.8 17.6 20.6 0  
    4    Elitest P   (96): A     84.4  9.3 91.6 21.8 53.1 63.5  
          Elitest N  (61)    23  8.2 34.4 11.5 14.7 16.4  
    5    Elitest P   (102): B2    100  5.9 7.8 72.5 45 46.1  
           Elitest N  (15)    100  0 0 26.6 20 13.3  
 




          
   Elitest P (213)    100  8.4 45.5 50.2 49.3 49.3  
   Elitest P (13)    0  7.7 77 0 30.8 23  
   Elitest N (54)    100  13 27.8 16.7 26 14.8  
   Elitest N (216)    0  7.4 14.8 17.1 17.6 3.7  
 622 
a Elitest P and N categories in the global population have each been further classified into two subcategories in the global population analyzed on the basis of 623 







Reactivity (percentage of positive reactions) in 4 peptide ELISAs (98M, 126M1, 126M2, 139), using sera from SRLV diseased and asymptomatic 629 
seropositive animals (by Chekit or Elitest standard tests) from flocks located in Castilla-León and Aragón and belonging to the neurological (type A) and 630 
arthritic (type B) outbreaks, respectively.   631 
 
Group  Status Standard test Peptide ELISA 




















88.5 100  91.7 21.9 53.1 63.5 
5  Arthritic disease 
(n=12) 
100 100  8.3 91.7 58.3 83.3 
 Asymptomatic 
(n=117) 
100 87.2  6.8 66.7 42.7 40.1 
* p<0.0001: Statistical differences using Fisher’s exact test were found between diseased vs. asymptomatic animals from the same 632 
outbreak only in the peptide 139 ELISA. 633 
27 
 
Table 5       634 
Sensitivity and specificity of peptide ELISA and standard test (Elitest) 
according to the SRLV genotype involved. Best performance peptide ELISA is 
reported in bold. Standard Elitest data are highlighted in italics. 
 
Genotype ELISA Sensitivity (95% CI) Specificity (95% CI) 
A p91 0.750 (0.616 - 0.856) 0.168 (0.108 - 0.243) 
 p98M 0.857 (0.738 - 0.936) 0.985 (0.946 - 0.998) 
 p126M1 0.393 (0.265 - 0.532) 0.864 (0.793 - 0.917) 
 p126M2 0.679 (0.540 - 0.797) 0.879 (0.811 - 0.929) 
 p139 0.607 (0.468 - 0.735) 0.846 (0.772 - 0.903) 
 Elitest 0.911 (0.804 - 0.970) 0.898 (0.833 - 0.945) 
B p91 0.636 (0.407 - 0.828) 0.237 (0.167 - 0.319) 
 p98M 0.364 (0.172 - 0.593) 0.947 (0.894 - 0.978) 
 p126M1 0.818 (0.597 - 0.948) 0.955 (0.904 - 0.983) 
 p126M2 0.773 (0.546 - 0.922) 0.924 (0.865 - 0.963) 
 p139 0.591 (0.364 - 0.793) 0.900 (0.835 - 0.946) 
 Elitest 0.727 (0.498 - 0.893) 0.898 (0.833 - 0.945) 
E p91 0.750 (0.349 - 0.968) 0.496 (0.408 - 0.585) 
 p98M 0.750 (0.349 - 0.968) 0.636 (0.548 - 0.718) 
 p126M1 0.750 (0.349 - 0.968) 0.667 (0.579 - 0.746) 
 p126M2 0.625 (0.245 - 0.915) 0.583 (0.494 - 0.668) 
 p139 0.625 (0.245 - 0.915) 0.523 (0.434 - 0.611) 
 Elitest 0.875 (0.473 - 0.997) 0.805 (0.725 - 0.869) 






Fig. 1. Phylogenetic tree involving 60 SRLV gag sequences. These include the 37 638 
sequences genoyped used in this study (reported in bold) and reference sequences obtained 639 
from GenBank. The SRLV genotypes and subtypes are indicated. GenBank accession 640 
numbers are indicated within brackets. Posterior probability for each node is indicated 641 
above branches. 642 
Fig.  2.  Distribution of optical density values obtained in the four synthetic peptide 643 
ELISAs. Peptides used were: 98M (top left panel), 126M1 (top right panel), 126M2 644 
(bottom left panel) and 139 (bottom right panel). Sera tested in these ELISAs were from 71 645 
animals infected with A (48), B (23) and E (8) SRLV genetic types and 130 negative 646 
animals. 647 
Fig. 3. ROC curves illustrating sensitivity and specificity values of five ELISAs 648 
(corresponding to peptides 91, 98M, 126M1, 126M2 and 139) and the Elitest standard 649 
ELISA found in groups of sera distributed according to genotypes A (top panel) B (middle 650 
panel) and E (bottom panel). 651 
 652 
Fig. 1S. ANNEX 1: Oligonucleotides used in different PCRs to obtain the gag and env 653 
nucleotide sequences of SRLV from natural infections in North Central Spain.  ANNEX II. 654 
Synthetic peptides used in this study for small ruminant lentivirus specific antibody 655 
detection by indirect ELISA. 656 
Fig. 2S. Alignment of partial SU sequences obtained in this work and GeneBank 657 
sequences. The SU5 region corresponds to base pairs 7720 to 7907 and amino acids 597 to 658 
632 of the CAEV-CO molecular clone (accession number M33677). Accession numbers 659 
29 
 
are indicated for each sequence. The first eight sequences were obtained in this work from 660 
the Castilla-León neurological outbreak (accession numbers JN184379 to JN184394). The 661 
98M peptide sequence (consensus) underlined (top), starts at the end of the constant SU5 662 
region of the ENV SU protein. The hydrophilic-antigenic region is outlined within a 663 
square. The beginning of the SU5 domain of the ENV protein (Mordasini et al., 2006) is 664 
indicated by an arrow. See also Glaria et al. (2012) on a section of this figure lacking 665 
several of the Spanish sequences her illustrated and other known sequences. 666 
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